share_log

博瑞医药(688166.SH):卡前列素氨丁三醇注射液获批上市

Borui Pharmaceutical (688166.SH): Caprost and trometaminotriol injections approved for marketing

Zhitong Finance ·  Mar 15 05:02

Borui Pharmaceutical (688166.SH) issued an announcement. Recently, Borui Pharmaceutical (Suzhou) Co., Ltd., a wholly-owned subsidiary of the company...

Zhitong Finance App News, Borui Pharmaceutical (688166.SH) issued an announcement. Recently, Borui Pharmaceutical (Suzhou) Co., Ltd., a wholly-owned subsidiary of the company, received the “caprost tromethrin injection” and “drug registration certificate” issued by the State Drug Administration. Caprost and tromethotriol injections are mainly suitable for abortions between 13 and 20 weeks of pregnancy and postpartum hemorrhage caused by uterine contraction relaxation due to ineffective conventional treatment methods.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment